dc.identifier.citation | van Heerden, J., Esterhuizen, T., Jbebli, E., Fedhila Ben Ayed, F., Rhayem, S., Chabchoub, I., ... & Davidson, A. Pediatric low-grade glioma in Africa: A baseline study before the implementation of Global Initiative for Childhood Cancer strategies. Frontiers in Cancer Control and Society, 3, 1528695. | en_US |
dc.description.abstract | Introduction: Pediatric low-grade glioma (LGG) is a World Health Organization
(WHO) Global Initiative for Childhood Cancer (GICC) index tumor constituting
up to a third of pediatric central nervous system (CNS) tumors. The
baseline characteristics, survival, and management resources for pediatric LGG in Africa are unknown. We aimed to evaluate the pediatric neuro-
oncology multidisciplinary team resources, epidemiology, and survival outcomes
of pediatric LGG in Africa to document baseline information prior to
GICC implementation.
Methods: The study consisted of two parts: a survey completed by
African pediatric oncology units (POU) to evaluate the local resources and a
retrospective evaluation of data to determine the 5-year overall survival (OS)
for patients under 18 years diagnosed with LGG between 2008 and 2018. Data
were described in frequencies and percentages. Survival was expressed with
Kaplan–Meier curves.
Results: Five-hundred and eighty-eight patients were included from fifteen
POUs in six countries: South Africa (45.9%), Egypt (30.8%), Morocco (12.6%),
Mali (4.4%), Tunisia (3.6%) and Uganda (2.7%). The median age was 4.4 years
(interquartile range 2.4–7.3 years). The most common primary tumor site was
the brainstem (n = 125, 21.3%), the most common histology was pilocytic
astrocytoma (n = 270, 47.5%), the majority of tumors (n = 292, 93%) were
localized, and 40 (6.8%) patients had neurofibromatosis. Complete resection was
obtained in 99 (16.8%) cases, incomplete resection in 179 (30.4%), and no surgery
or biopsy only was performed in 310 (52.7%) cases. One hundred and forty-
seven (25.3%) of the 580 patients with a documented radiotherapy status, were
irradiated, and 320 (54.4%) received chemotherapy. Only 259 (15.3%) patients
received chemotherapy of which the most common chemotherapy regimen was
vincristine-carboplatin (n = 220, 84.9%). The 5-year OS was 90.5% ± 1.6%. The 5-
year OS in Tunisia was 95.1% ± 1.1%, 92.4% ± 2.1% in Egypt, 89.0% ± 3.2% in South
Africa, 70.7% ± 6.7% in Morocco and 66.7% ± 15.7% in Uganda (p < 0.001). Four
of the 41 (9.8%) responding countries reported having pediatric neuro-oncology
subspecialists, and four (9.8%) had national pediatric LGG protocols. In Africa
there is one radiotherapy center per 2,235,125 children and one neurosurgeon
per 304,685 children, with ∼70% of these resources accessible in four countries.
Discussion: Due to several resource challenges and developing treatment
centers, only fifteen pediatric oncology units from six countries participated.
We documented a baseline 5-year OS of 94.9% for LGG in African children.
To obtain an accurate estimation of pediatric LGG survival in Africa, increasing
participation from a wider range of countries, especially poorly resourced
settings, is necessary.
KEYWORDS
Africa, low-grade glioma, children, outcomes, systems, GICC | en_US |